LivaNova PLC (NASDAQ:LIVN) Files An 8-K Other Events

LivaNova PLC (NASDAQ:LIVN) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events

On May 2, 2017, LivaNova PLC (“LivaNova”) announced that it had
acquired Caisson Interventional, LLC (“Caisson”), a privately
held clinical-stage medical device company. Prior to the
acquisition, LivaNova owned approximately 49% of the issued and
outstanding equity of Caisson. to the terms of a Unit Purchase
Agreement, LivaNova acquired the outstanding units of Caisson not
otherwise owned by LivaNova, in exchange for its agreement to pay
up to $72 million, net of $6 million of debt forgiveness. The
first payment of $18 million will be made at closing with the
balance paid on a schedule driven primarily by regulatory
approvals and sales earn outs. As a result of the acquisition,
LivaNova expects to recognize a pre-tax non-cash gain during the
second quarter on the $15 million book value of its existing
investment in Caisson.
A copy of LivaNova’s press release dated May 2, 2017 announcing
the acquisition is attached hereto as Exhibit 99.1
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
Description
99.1
Press Release issued by LivaNova PLC dated May 2, 2017


About LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing. The CRM business unit develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM offers products, including leads and delivery systems, and information systems. The Neuromodulation business unit designs, develops and markets neuromodulation-based medical devices for the treatment of epilepsy and depression. Through the Neuromodulation business unit, the Company markets its implantable VNS Therapy systems that deliver vagus nerve stimulation therapy for the treatment of epilepsy and depression.

LivaNova PLC (NASDAQ:LIVN) Recent Trading Information

LivaNova PLC (NASDAQ:LIVN) closed its last trading session up +1.33 at 54.20 with 323,323 shares trading hands.

An ad to help with our costs